Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial
Jeffrey M Statland,Dan Moore,Yunxia Wang,Maureen Walsh,Tahseen Mozaffar,Lauren Elman,Sharon P Nations,Hiroshi Mitsumoto,J Americo Fernandes,David Saperstein,Ghazala Hayat,Laura Herbelin,Chafic Karam,Jonathan Katz,Heather M Wilkins,Abdulbaki Agbas,Russell H Swerdlow,Regina M Santella,Mazen M Dimachkie,Richard J Barohn,Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium,Russell Swerdlow,Jeffrey Statland,Melanie Glenn,Mamatha Pasnoor,Kelley Emmons,Kathryn Johns,Yolanda Harness,Robert G Miller,Dallas Forshew,Marguerite Engel,Namita Goyal,Tiyonnoh Cash,Veena Mathew,Veronica Martin,Todd Levine,Lynn Flynne,Diana Dimtrov,Leo McCluskey,Kelly Almasy,Mary Kelley,J Americo M Fernandes,Pariwat Thaisetthawatkul,Carolyn Peterson,Cindy Cowardin,Peggy Heires,Sharon Nations,Jaya Trivedi,Nina F Gorham,Steve Hopkins,Susan Brown,Sonya Aziz-Zaman,Jonathan Hupf,Nicole Armstrong,Brittany McHale,Heather Wilkins,Jessica Sage,Sharice Hall,Regina Santella,Irina Gurvich,Anthony Amato,Richard Bedlack,Carlayne Jackson,Gary Cutter,Gil Wolfe,Ericka Simpson
DOI: https://doi.org/10.1002/mus.26335
Abstract:Introduction: Rasagiline is a monoamine oxidase B (MAO-B) inhibitor with possible neuroprotective effects in patients with amyotrophic lateral sclerosis (ALS). Methods: We performed a randomized, double-blind, placebo-controlled trial of 80 ALS participants with enrichment of the placebo group with historical controls (n = 177) at 10 centers in the United States. Participants were randomized in a 3:1 ratio to 2 mg/day rasagiline or placebo. The primary outcome was average slope of decline on the ALS Functional Rating Scale-Revised (ALSFRS-R). Secondary measures included slow vital capacity, survival, mitochondrial and molecular biomarkers, and adverse-event reporting. Results: There was no difference in the average 12-month ALSFRS-R slope between rasagiline and the mixed placebo and historical control cohorts. Rasagiline did not show signs of drug-target engagement in urine and blood biomarkers. Rasagiline was well tolerated with no serious adverse events. Discussion: Rasagiline did not alter disease progression compared with controls over 12 months of treatment. Muscle Nerve 59:201-207, 2019.